ReNeuron Group Life Sciences Firm will initiate Phase IIb clinical study of CTX cell therapy sure to interest Scotland’s life science research community. The study, designated PISCES III, is a randomised, placebo-controlled clinical trial involving 110 patients across 40 clinical trial sites in the U.S.. Patients with stable post-stroke disability are entered into the study six to 12 months after their stroke and are randomized to receive either the CTX therapy or placebo treatment.
The primary end-point of the study is a comparison of the proportion of patients in the treated and placebo arms showing a clinically significant improvement on the Modified Rankin Scale, a measure of disability and dependence, at six months post-treatment compared with baseline. Top-line results from the study are expected in early 2020.
Who is ReNeuron Group? They engage in the research, development, and commercial exploitation of stem cell technologies for therapeutic and non-therapeutic applications. Formed in 1997, they have raised over $164 million.
It develops stem cell therapies for a range of neurodegenerative diseases and other conditions, including Parkinson’s disease, Type 1 diabetes, and diseases of the retina. The company’s therapeutic product pipeline includes ReN001, a pre-clinical development stage therapy for disabled stroke patients. Its other therapeutic and non-therapeutic programs in pre-clinical trials comprise ReN002 for diabetes, ReN003 for retinal diseases, ReN004 for Parkinson’s disease, and ReN005 for Huntington’s disease. ReNeuron Group also develops and markets neural stem cell lines that include ReNcell VM and ReNcell CX. The company was founded in 1997 and is headquartered in Guildford, the United Kingdom.